IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v25y2007i5p429-442.html
   My bibliography  Save this article

Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer

Author

Listed:
  • J. Millar
  • Michael Millward

Abstract

The results suggest that trastuzumab as adjuvant therapy for early breast cancer may be cost effective when given over either 52 or 9 weeks at current acquisition costs in Australia. However, the overall budget impact of the 52-week course is significant, and the 9-week course appears economically attractive. Copyright Adis Data Information BV 2007

Suggested Citation

  • J. Millar & Michael Millward, 2007. "Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer," PharmacoEconomics, Springer, vol. 25(5), pages 429-442, May.
    • Handle: RePEc:spr:pharme:v:25:y:2007:i:5:p:429-442
    DOI: 10.2165/00019053-200725050-00006
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200725050-00006
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200725050-00006?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Caroline S Clarke & Rachael M Hunter & Ian Shemilt & Victoria Serra-Sastre, 2017. "Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective," PLOS ONE, Public Library of Science, vol. 12(3), pages 1-19, March.
    2. Yong Yi Lee & J Lennert Veerman & Jan J Barendregt, 2013. "The Cost-Effectiveness of Laparoscopic Adjustable Gastric Banding in the Morbidly Obese Adult Population of Australia," PLOS ONE, Public Library of Science, vol. 8(5), pages 1-10, May.
    3. Savvas S. Ioannou & Yiola Marcou & Eleni Kakouri & Michael A. Talias, 2020. "Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective," IJERPH, MDPI, vol. 17(12), pages 1-20, June.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:25:y:2007:i:5:p:429-442. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.